Filing Flows › Atara Biotherapeutics (ATRA) › Q1 2025
Atara Biotherapeutics (ATRA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Atara Biotherapeutics (ATRA) reported revenue of $98.1M for the first quarter 2025 (Q1 2025), +259% from a year earlier and +200% from the quarter before. Operating margin was 39.5%, net earnings $38.0M (38.7% of revenue).
Atara Biotherapeutics, Q1 2025: revenue $98.1M (+259% year over year), operating margin 39.5%, net earnings $38.0M, operating cash flow −$28.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $98.1M | +200% | +259% |
| Operating profit | $38.8M | — | — |
| Net earnings | $38.0M | — | — |
| Operating cash flow | −$28.1M | — | — |
What changed
Revenue was $98.1M in Q1 2025, up 259% year over year and up 200% from the previous quarter.
Operating profit was $38.8M, a 39.5% margin (up 153.8 points year over year). Total costs grew 1% against revenue growth of 259%. The fastest-growing cost line was Other operating costs (+930%). Net earnings were $38.0M. The effective tax rate was 0.0%.
Operating cash flow was −$28.1M. Non-cash charges added back $1.8M of depreciation and amortization and $4.2M of share-based compensation. Working capital and other items used $72.2M.
Questions
What was Atara Biotherapeutics' revenue in the first quarter 2025?
Atara Biotherapeutics (ATRA) reported revenue of $98.1M for the first quarter 2025 (Q1 2025), +259% from a year earlier and +200% from the quarter before.
Was Atara Biotherapeutics profitable in the first quarter 2025?
Operating profit was $38.8M (39.5% of revenue) and net earnings $38.0M.